Publication:
A novel hybrid method named electron conformational genetic algorithm as a 4D QSAR investigation to calculate the biological activity of the tetrahydrodibenzazosines

dc.contributor.authorSahin, Kader
dc.contributor.authorSaripinar, Emín
dc.contributor.institutionSahin, Kader, Department of Biophysics, Bahçeşehir Üniversitesi, Istanbul, Turkey
dc.contributor.institutionSaripinar, Emín, Department of Chemistry, Erciyes Üniversitesi, Kayseri, Turkey
dc.date.accessioned2025-10-05T15:48:41Z
dc.date.issued2020
dc.description.abstractTo understand the structure–activity correlation of a group of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3, we have performed a combined genetic algorithm (GA) and four-dimensional quantitative structure–activity relationship (4D-QSAR) modeling study. The computed electronic and geometry structure descriptors were regulated as a matrix and named as electron-conformational matrix of contiguity (ECMC). A chemical property-based pharmacophore model was developed for series of tetrahydrodibenzazocines by EMRE software package. GA was employed to choose an optimal combination of parameters. A model has been developed for estimating anticancer activity quantitatively. All QSAR models were established with 40 compounds (training set), then they were considered for selective capability with additional nine compounds (test set). A statistically valid 4D-QSAR ((Formula presented.), (Formula presented.) and q2 = 0.650) with good external set prediction was obtained. © 2020 Elsevier B.V., All rights reserved.
dc.identifier.doi10.1002/jcc.26154
dc.identifier.endpage1104
dc.identifier.issn1096987X
dc.identifier.issn01928651
dc.identifier.issue11
dc.identifier.pubmed32058616
dc.identifier.scopus2-s2.0-85079436464
dc.identifier.startpage1091
dc.identifier.urihttps://doi.org/10.1002/jcc.26154
dc.identifier.urihttps://hdl.handle.net/20.500.14719/10490
dc.identifier.volume41
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc. P.O.Box 18667 Newark NJ 07191-8667
dc.relation.sourceJournal of Computational Chemistry
dc.subject.authorkeywordsDrug Design
dc.subject.authorkeywordsGenetic Algorithm
dc.subject.authorkeywordsMolecular Modeling
dc.subject.authorkeywordsPharmacophore
dc.subject.authorkeywordsTetrahydrodibenzazocines
dc.subject.authorkeywordsHydroxysteroid Dehydrogenase
dc.subject.authorkeywords17-hydroxysteroid Dehydrogenases
dc.subject.authorkeywordsAntineoplastic Agents
dc.subject.authorkeywordsAzocines
dc.subject.authorkeywordsEnzyme Inhibitors
dc.subject.authorkeywordsBioactivity
dc.subject.authorkeywordsBioinformatics
dc.subject.authorkeywordsComputational Chemistry
dc.subject.authorkeywordsConformations
dc.subject.authorkeywordsDehydrogenation
dc.subject.authorkeywordsMolecular Graphics
dc.subject.authorkeywordsMolecular Modeling
dc.subject.authorkeywordsPharmacodynamics
dc.subject.authorkeywordsAnticancer Activities
dc.subject.authorkeywordsDrug Design
dc.subject.authorkeywordsHydroxysteroid Dehydrogenase
dc.subject.authorkeywordsOptimal Combination
dc.subject.authorkeywordsPharmacophore Modeling
dc.subject.authorkeywordsPharmacophores
dc.subject.authorkeywordsQuantitative Structures
dc.subject.authorkeywordsTetrahydrodibenzazocines
dc.subject.authorkeywordsGenetic Algorithms
dc.subject.authorkeywordsAntineoplastic Agent
dc.subject.authorkeywordsAzocine Derivative
dc.subject.authorkeywordsEnzyme Inhibitor
dc.subject.authorkeywordsHydroxysteroid Dehydrogenase
dc.subject.authorkeywordsAlgorithm
dc.subject.authorkeywordsChemistry
dc.subject.authorkeywordsConformation
dc.subject.authorkeywordsDrug Screening
dc.subject.authorkeywordsElectron
dc.subject.authorkeywordsMolecular Model
dc.subject.authorkeywordsQuantitative Structure Activity Relation
dc.subject.authorkeywords17-hydroxysteroid Dehydrogenases
dc.subject.authorkeywordsAlgorithms
dc.subject.authorkeywordsAntineoplastic Agents
dc.subject.authorkeywordsAzocines
dc.subject.authorkeywordsDrug Screening Assays, Antitumor
dc.subject.authorkeywordsElectrons
dc.subject.authorkeywordsEnzyme Inhibitors
dc.subject.authorkeywordsModels, Molecular
dc.subject.authorkeywordsMolecular Conformation
dc.subject.authorkeywordsQuantitative Structure-activity Relationship
dc.subject.indexkeywordsBioactivity
dc.subject.indexkeywordsBioinformatics
dc.subject.indexkeywordsComputational chemistry
dc.subject.indexkeywordsConformations
dc.subject.indexkeywordsDehydrogenation
dc.subject.indexkeywordsMolecular graphics
dc.subject.indexkeywordsMolecular modeling
dc.subject.indexkeywordsPharmacodynamics
dc.subject.indexkeywordsAnticancer activities
dc.subject.indexkeywordsDrug Design
dc.subject.indexkeywordsHydroxysteroid dehydrogenase
dc.subject.indexkeywordsOptimal combination
dc.subject.indexkeywordsPharmacophore modeling
dc.subject.indexkeywordsPharmacophores
dc.subject.indexkeywordsQuantitative structures
dc.subject.indexkeywordstetrahydrodibenzazocines
dc.subject.indexkeywordsGenetic algorithms
dc.subject.indexkeywordsantineoplastic agent
dc.subject.indexkeywordsazocine derivative
dc.subject.indexkeywordsenzyme inhibitor
dc.subject.indexkeywordshydroxysteroid dehydrogenase
dc.subject.indexkeywordsalgorithm
dc.subject.indexkeywordschemistry
dc.subject.indexkeywordsconformation
dc.subject.indexkeywordsdrug screening
dc.subject.indexkeywordselectron
dc.subject.indexkeywordsmolecular model
dc.subject.indexkeywordsquantitative structure activity relation
dc.subject.indexkeywords17-Hydroxysteroid Dehydrogenases
dc.subject.indexkeywordsAlgorithms
dc.subject.indexkeywordsAntineoplastic Agents
dc.subject.indexkeywordsAzocines
dc.subject.indexkeywordsDrug Screening Assays, Antitumor
dc.subject.indexkeywordsElectrons
dc.subject.indexkeywordsEnzyme Inhibitors
dc.subject.indexkeywordsModels, Molecular
dc.subject.indexkeywordsMolecular Conformation
dc.subject.indexkeywordsQuantitative Structure-Activity Relationship
dc.titleA novel hybrid method named electron conformational genetic algorithm as a 4D QSAR investigation to calculate the biological activity of the tetrahydrodibenzazosines
dc.typeArticle
dcterms.referencesPoirier, Donald, Inhibitors of 17β-Hydroxysteroid dehydrogenases, Current Medicinal Chemistry, 10, 6, pp. 453-477, (2003), Scher, Howard I., Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer, Endocrine-Related Cancer, 11, 3, pp. 459-476, (2004), Sha, Jiaho A., Sequence of mouse 17β-hydroxysteroid dehydrogenase type 3 cDNA and tissue distribution of the type 1 and type 3 isoform mRNAs, Journal of Steroid Biochemistry and Molecular Biology, 60, 1-2, pp. 19-24, (1997), Koh, Eitetsue, Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues, Prostate, 53, 2, pp. 154-159, (2002), Spires, Thomas E., Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3), Prostate, 65, 2, pp. 159-170, (2005), Geissler, Wayne M., Male pseudohermaphroditism caused by mutations of testicular 17β–hydroxysteroid dehydrogenase 3, Nature Genetics, 7, 1, pp. 34-39, (1994), Luu-Thé, Van, Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition, Journal of Steroid Biochemistry and Molecular Biology, 55, 5-6, pp. 581-587, (1995), Robert, Jacques, Multidrug Resistance Reversal Agents, Journal of Medicinal Chemistry, 46, 23, pp. 4805-4817, (2003), Hassan, Saadia Bashir, Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo, Cancer Chemotherapy and Pharmacology, 55, 1, pp. 47-54, (2005), Jin, Shan, Computer-based de novo design, synthesis, and evaluation of boronic acid-based artificial receptors for selective recognition of dopamine, ChemBioChem, 9, 9, pp. 1431-1438, (2008)
dspace.entity.typePublication
local.indexed.atScopus
person.identifier.scopus-author-id57211550406
person.identifier.scopus-author-id6603068833

Files